Skip to main content
Fig. 3 | Molecular Cancer

Fig. 3

From: ARHGEF15 overexpression worsens the prognosis in patients with pancreatic ductal adenocarcinoma through enhancing the motility and proliferative activity of the cancer cells

Fig. 3

ARHGEF15 expression is associated with activation of the Rho-family proteins in several cell lines. a ARHGEF15 expression levels in untreated Hs766T cells (Ctrl), Hs766T cells treated with negative control siRNA (siNC) or siRNA for ARHGEF15 were assayed by both real-time RT-PCR and Western blotting. b Confirmation by the active RhoA/Cdc42/Rac1 pull-down assay. HeLa cell lysates treated with GDP (to inactivate the Rho-pathway proteins) or GTP (to activate the Rho-pathway proteins) were subjected to pull-down assay for the active Rho-family proteins to examine the degree of activation of the Rho-family proteins. c RhoA, Cdc42 and Rac1 activation in Hs766T cells after knockdown of endogenous ARHGEF15 measured by the active RhoA/Cdc42/Rac1 pull-down assay. Overexpression of ARHGEF15 in d AsPC-1 cells and e MIAPaCa-2 cells. RhoA, Cdc42 and Rac1 activation in f AsPC-1 cells and g MIAPaCa-2 cells transfected with the ARHGEF15 expression vector assessed by the active RhoA/Cdc42/Rac1 pull-down assay (n = 3). The scale bars represent 200 μm

Back to article page